trial

Staccato Loxapine in Agitation (Proof of Concept)

NCTId NCT00369577
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 129 (actual)
Sponsored by Alexza Pharmaceuticals, Inc.
Primary completion 2007-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
129 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2006-08
Primary completion
2007-01
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Inhaled Loxapine 5 mgInhaled Loxapine 10 mg

Sponsors

Alexza Pharmaceuticals, Inc.Lead Sponsor

Investigators

1
Daniel Zimbroff, MDPrincipal Investigator

Sites

1 total
Upland, United States

Linked catalysts

1
Staccato Loxapine in Agitation (Proof of Concept) — primary completion2007-01

Facts & assertions

4 sourced
Enrollment
129
Phase
PHASE2
Primary Completion Date
2007-01
Status
COMPLETED
relationships
The graph out of here
drug
Inhaled Loxapine 5 mg
drug
Inhaled Loxapine 10 mg
drug
lead_sponsor
Alexza Pharmaceuticals, Inc.
company
indication
Schizophrenia
indication
Psychomotor Agitation
indication
Schizophrenia
indication
investigator
Daniel Zimbroff, MD
person